Product Name: MLK3-pS281
Product Number: AB-PK718
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Mixed-lineage protein-serine kinase 3; Mitogen-activated protein kinase kinase kinase 11
Target Alias: Kinase MLK3; M3K11; MAP3K11; MAPKKK11; MEKK11; Mitogen activated protein kinase kinase kinase 11; Mixed lineage kinase 3; MLK-3; SPRK; MGC17114; CCDS8107.1; ENSG00000173327
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK718
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S281
Protein UniProt: Q16584
Protein SigNET: Q16584
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Target Alias: Kinase MLK3; M3K11; MAP3K11; MAPKKK11; MEKK11; Mitogen activated protein kinase kinase kinase 11; Mixed lineage kinase 3; MLK-3; SPRK; MGC17114; CCDS8107.1; ENSG00000173327
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK718
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S281
Protein UniProt: Q16584
Protein SigNET: Q16584
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human MLK3 (MAP3K11) sequence peptide Cat. No.: PE-04AOB85
Antibody Immunogen Sequence: TQM(pS)AAG(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues T278 to G284; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Antibody Immunogen Sequence: TQM(pS)AAG(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues T278 to G284; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 93-100 kDa.
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 93-100 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: No significant cross-reactivities detected in HeLa cells treated with phenylarsine oxide (PAO)+vanadate (homogenized in SDS-PAGE sample buffer), except for a strong 50kDa cross-reactive protein ; medium immunoreactive 50 kDa protein in EGF-treated A431cells (SDS-PAGE buffer-extracted); Clean, but strong background >75K in insulin-treated MCF7 cells (SDS-PAGE buffer extracted).
Related Product 1: MLK3-pS281 blocking peptide
Related Product 2: MLK3-pT277 + pS281 phosphosite-specific antibody (Cat. No.: AB-PK870)
Antibody Cross Reactivity: No significant cross-reactivities detected in HeLa cells treated with phenylarsine oxide (PAO)+vanadate (homogenized in SDS-PAGE sample buffer), except for a strong 50kDa cross-reactive protein ; medium immunoreactive 50 kDa protein in EGF-treated A431cells (SDS-PAGE buffer-extracted); Clean, but strong background >75K in insulin-treated MCF7 cells (SDS-PAGE buffer extracted).
Related Product 1: MLK3-pS281 blocking peptide
Related Product 2: MLK3-pT277 + pS281 phosphosite-specific antibody (Cat. No.: AB-PK870)
Scientific Background: MLK3 (MAP3K11) is a protein-serine/threonine kinase of the TKL group and MLK family. It induces the indirect activation of B-Raf, MKK4 (MAP2K4), MKK7 (MAP2K7), JNK1 (MAPK8), MAPK14 and ERK1 (MAPK3). Homodimerization via the leucine zipper domains is required for autophosphorylation at T277 and S281 and increases phosphotransferase activity.
Figure 1. Epitope mapping of MLK3-pS281 antibody with similar phosphopeptides on dot blots.
Figure 2. Identification of phosphosites related to MLK3-pS281.
© Kinexus Bioinformatics Corporation 2017